R&D Pipeline (As of Oct 2018) Underlined items indicate changes from the previous announcement on July 27, 2018.
|
|
|
- Laura Turner
- 5 years ago
- Views:
Transcription
1 R&D Pipeline (As of Oct 2018) Underlined items indicate changes from the previous announcement on July 27, Oncology (1/2) enzalutamide MDV3100 (XTANDI ) Androgen receptor inhibitor Non-metastatic castration-resistant prostate cancer Non-metastatic hormone-sensitive prostate cancer Approved (Oct. 2018) / Europe P-III / US, Europe, Asia Pfizer Metastatic hormone-sensitive prostate cancer blinatumomab AMG 103 (BLINCYTO ) gilteritinib ASP2215 Anti-CD19 BiTE antibody FLT3/AXL inhibitor Relapsed or refractory B-cell acute lymphoblastic leukemia Relapsed or refractory acute myeloid leukemia Post-chemo maintenance acute myeloid leukemia Approved (Sep. 2018) / Japan Injection Amgen Approved (Sep. 2018) / Japan Filed (Mar. 2018) / US P-III / Europe, Asia In-house 39 Post-HSCT maintenance acute myeloid leukemia Newly diagnosed acute myeloid leukemia with low intensity induction of chemotherapy P-II/III / US, Europe, Japan, Asia Newly diagnosed acute myeloid leukemia with high intensity induction of chemotherapy P-I / US, Japan degarelix ASP3550 (GONAX ) zolbetuximab IMAB362 enfortumab vedotin ASG-22ME GnRH antagonist Prostate cancer (3-month formulation) Filed (Nov. 2017) / Japan Injection Ferring Anti-Claudin 18.2 Gastric and gastroesophageal junction adenocarcinoma Injection In-house (Ganymed) ADC targeting nectin-4 Urothelial cancer Injection In-house with Seattle Genetics) AGS-16C3F ADC targeting ENPP3 Renal cell carcinoma, Europe Injection In-house (ADC technology in-licensed from Seattle Genetics) ASP1650 Anti-Claudin 6 Testicular Cancer Injection In-house (Ganymed)
2 Oncology (2/2) ASP1235/AGS62P1 Acute myeloid leukemia P-I Injection In-house (ADC technology, EuCODE license from Ambrx) ASP8374/PTZ-201 Cancer P-I Injection Option agreement ASP1948/PTZ-329 Cancer P-I Injection Option agreement ASP1951/PTZ-522 Cancer P-I Injection Option agreement 40 Updates from the previous announcement (Jul. 2018): enzalutamide (MDV3100): Approved in Europe for high-risk non-metastatic castration-resistant prostate cancer in Oct Removed the previous description of approval in US. blinatumomab (AMG 103): Approved in Japan for relapsed or refractory B-cell acute lymphoblastic leukemia in Sep gilteritinib (ASP2215): Approved in Japan for FLT3 mutation-positive relapsed or refractory acute myeloid leukemia in Sep ASP1650: Added a Phase 2 program for testicular cancer. ASP1951/PTZ-522: Initiated clinical development for cancer. AGS67E: Discontinued Phase 1 program for lymphoid malignancies.
3 Immunology, Muscle disease and Ophthalmology peficitinib ASP015K JAK inhibitor Rheumatoid arthritis Filed (May 2018) / Japan In-house bleselumab ASKP1240 Anti-CD40 Recurrence of focal segmental glomerulosclerosis in de novo kidney transplant recipients Injection Kyowa Hakko Kirin ASP4070/ JRC2-LAMP-vax DNA vaccine for Japanese red cedar Pollinosis caused by Japanese red cedar P-II / Japan Injection Immunomic LAMP-vax technology ASP5094 Anti-alpha-9 integrin Rheumatoid arthritis P-II / Japan Injection In-house reldesemtiv CK Fast skeletal troponin activator Spinal muscular atrophy Cytokinetics Chronic obstructive pulmonary disease Molecular motor Amyotrophic lateral sclerosis 41 ASP7317 Cell therapy (Retinal pigment epithelium cell) Dry age-related macular degeneration, Stargardt s macular degeneration Injection In-house (Astellas Institute for Regenerative Medicine) MA-0211 Duchenne muscular dystrophy P-I In-house (Mitobridge) ASP0892 Peanut allergy P-I Injection Immunomic Cell therapy Mitochondria LAMP-vax technology Update from the previous announcement (Jul. 2018): tacrolimus (FK506): Removed the description of approval in US for granule formulation in pediatric use (prevention of rejection after organ transplantation) in May 2018.
4 Urology and Nephrology solifenacin YM905 Muscarine M 3 receptor antagonist Neurogenic detrusor overactivity Filed (Feb. 2017) / US In-house Focus Area Approach roxadustat ASP1517/FG-4592 mirabegron YM178 HIF stabilizer Anemia associated with chronic kidney disease Filed (Sep. 2018) / Japan FibroGen in patients on dialysis P-III / Europe Beta 3 receptor agonist Anemia associated with chronic kidney disease in patients not on dialysis Neurogenic detrusor overactivity P-III / Europe P-III / Japan P-III / Europe In-house ASP6294 ASP8302 Nerve Growth Factor (NGF) neutralization antibody Muscarine M 3 receptor positive allosteric modulator Bladder pain syndrome / Interstitial cystitis P-II / Europe Injection In-house Underactive bladder P-II / Europe, Japan In-house ASP7713 Underactive bladder P-I In-house 42 MA-0217 Acute kidney injury P-I Injection In-house (Mitobridge) Mitochondria Update from the previous announcement (Jul. 2018): solifenacin/mirabegron (EB178): Removed the description of approval in US for overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency in Apr roxadustat (ASP1517/FG-4592): Filed in Japan for anemia associated with chronic kidney disease in patients on dialysis in Sep YM311/FG-2216: Deleted the program for renal anemia from the pipeline list.
5 Others linaclotide ASP0456 (LINZESS ) romosozumab AMG 785 ipragliflozin ASP1941 (Suglat ) evolocumab AMG 145 (Repatha ) Guanylate cyclase-c receptor agonist Anti-Sclerostin Chronic constipation Approved (Aug. 2018) / Japan Ironwood Osteoporosis for those at high risk of fracture Filed (Dec. 2016) / Japan Injection Amgen SGLT2 inhibitor Type 1 diabetes Filed (Jan. 2018) / Japan In-house with Kotobuki) Anti-PCSK-9 Statin intolerant hypercholesterolemia Filed (Aug. 2018) / Japan Injection Amgen fidaxomicin Macrocyclic antibiotic Clostridium difficile infection P-III / Europe Merck 43 fezolinetant ESN364 NK3 receptor antagonist Menopause-related vasomotor symptoms P-I / Japan In-house (Ogeda) ASP0819 ASP4345 Calcium2+-activated K+ channel opener Dopamine D 1 receptor positive allosteric modulator Fibromyalgia In-house Cognitive impairment associated with schizophrenia In-house isavuconazole ASP9766 Azole antifungal Invasive aspergillosis and mucormycosis Injection Basilea ASP1807/CC8464 Neuropathic pain P-I Chromocell MucoRice-CTB Prophylaxis of diarrhea caused by Vibrio cholerae P-I The Institute of Medical Science, the University of Tokyo Updates from the previous announcement (Jul. 2018): fidaxomicin: Removed the description of approval in Japan for infectious enteritis (bacrerial target: Clostridium difficile ) in Jul linaclotide (ASP0456): Approved in Japan for chronic constipation in Aug evolocumab (AMG 145): Filed in Japan for statin intolerant hypercholesterolemia in Aug isavuconazole (ASP9766): Added a Phase 2 program for invasive aspergillosis and mucormycosis. ASP6981: Discontinued Phase 1 program for congnitive impairment associated with schizophrenia.
R&D Pipeline (As of Jul 2018) Underlined items indicate changes from the previous announcement on Apr 26, 2018.
R&D Pipeline (As of Jul 2018) Underlined items indicate changes from the previous announcement on Apr 26, 2018. Oncology (1/2) MDV3100 enzalutamide (XTANDI ) Androgen receptor inhibitor Non-metastatic
*Compounds with "In-house" in this column include ones discovered by collaborative research.
AGS67E Lymphoid malignancies P-I Injection In-house (ADC technology in-licensed from Seattle Genetics) AGS62P1 Acute myeloid leukemia P-I Injection In-house (ADC technology, EuCODE license from Ambrx)
R&D Pipeline (As of Apr 2018) Underlined items indicate changes from the previous announcement on Jan 31, 2018.
R&D Pipeline (As of Apr 2018) Underlined items indicate changes from the previous announcement on Jan 31, 2018. Oncology (1/2) MDV3100 enzalutamide Androgen receptor inhibitor Castration-resistant prostate
R&D Pipeline (As of April 2017)
R&D Pipeline (As of April 2017) Underlined items indicate changes from the previous announcement on January 31, 2017. Oncology (1/2) MDV3100 enzalutamide Androgen receptor inhibitor Metastatic castration-resistant
R&D Pipeline (As of July 2016) 1. Global Development Underlined items indicate for changes from the previous announcement on May 11, (1) Regulat
R&D Pipeline (As of July 2016) 1. Global Development Underlined items indicate for changes from the previous announcement on May 11, 2016. (1) Regulatory decision *Compounds with "" in this column include
R&D Pipeline (May 2014) 1. Global Development (1) Approved Product Name (Approval Date) Classification Target Disease Area * MDV3100 enzalutamide XTAN
R&D Pipeline (May 2014) 1. Global Development (1) Approved Product Name (Approval Date) Classification Target Disease Area * MDV3100 enzalutamide XTANDI (Mar. 2014) Androgen receptor inhibitor
(2) Phase-lll / Phase-ll (2/3) ASP7487 (OSI-906) linsitinib IGF-1R/IR tyrosine kinase inhibitor Adrenocortical carcinoma Ovarian cancer, Non-small cel
R&D Pipeline (February 2012) 1. Global Development (1) Filed YM178 mirabegron Beta 3 receptor agonist Overactive bladder associated with symptoms of urgency, urinary frequency, and urge urinary incontinece
R&D Pipeline (May 2010)
R&D Pipeline (May 2010) 1 Global development (1) Filed Stage in the Most Advanced Territory YM617 tamsulosin Alpha-1 receptor antagonist Lower urinary tract syndrome in male patients (June 2007) New indication
(3) Phase-lll / Phase-ll (1/3) Stage in the most advanced territory EC905 solifenacin/ tamsulosin Concomitant use of solifenacin and tamsulosin Lower
R&D Pipeline (November 2011) 1. Global Development (1) Approved telavancin Product Name (Approval Date) VIBATIV (Sep. 2011) Classification Lipoglycopeptide antibiotic Therapeutic Target Treatment of adults
Q3/FY2017 FINANCIAL RESULTS
Q3/FY2017 FINANCIAL RESULTS ENDED DECEMBER 31, 2017 Chikashi Takeda Chief Financial Officer Astellas Pharma Inc. January 31, 2018 CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION 2 In this material,
Q2/FY2018 FINANCIAL RESULTS
Q2/FY2018 FINANCIAL RESULTS ENDED SEPTEMBER 30, 2018 Kenji Yasukawa, Ph.D President and CEO Astellas Pharma Inc. October 31, 2018 CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION 2 In this material,
Q3/FY2016 FINANCIAL RESULTS
Q3/FY2016 FINANCIAL RESULTS ENDED DECEMBER 31, 2016 Yasumasa Masuda Senior Corporate Executive, Chief Financial Officer Astellas Pharma Inc. January 31, 2017 CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING
R&D Pipeline (May 2006)
R&D Pipeline (May 2006) 1Japan (1)Approved Product Name (Code No) Vesicare (YM905) Funguard (FK463) (Approval Date ) solifenacin (April 2006) micafungin (April 2006) Urinary frequency, urinary incontinence
Q1/FY2016 FINANCIAL RESULTS
Q1/FY2016 FINANCIAL RESULTS ENDED JUNE 30, 2016 Yasumasa Masuda Senior Corporate Executive, Chief Financial Officer Astellas Pharma Inc. July 29, 2016 CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION
R&D Pipeline (November 2006)
R&D Pipeline (November 2006) 1Japan (1)Filed Code No Generic Name (Filing Date ) Therapeutic Target Classification YM177 celecoxib (Dec 2002) Rheumatoid arthritis, osteoarthritis, low back pain, etc Cyclooxygenase-II
Maximizing the Product Value
Business Review Review of Operations by Therapeutic Area Astellas is working to steadily grow and maximize the value of products developed through its investments over the years, including its growth drivers
Pfizer Independent Grants for Learning & Change Track 2- Annual Meetings: Submission Deadlines, Areas of Interest & Educational Goals
In order to submit a request for general meeting support through Track 2- Annual Meetings the answer to the following questions must be Yes : Does the activity align with Pfizer s areas of interest? (listed
Financial Results for FY2014 Ended March 31, 2015
0 Financial Results for FY2014 Ended March 31, 2015 May 11, 2015 Yoshihiko Hatanaka President and CEO Astellas Pharma Inc. 1 Cautionary Statement Regarding Forward-Looking Information This material includes
DEVELOPMENT R&D MEETING Sef Kurstjens, M.D., Ph.D. Chief Medical Officer Astellas Pharma, Inc. December 8, 2016
DEVELOPMENT R&D MEETING 2016 Sef Kurstjens, M.D., Ph.D. Chief Medical Officer Astellas Pharma, Inc. December 8, 2016 DEVELOPMENT PURPOSE 2 Turn innovative science into value for patients by characterizing
2Q/FY2015 Financial Results
2Q/FY2015 Financial Results Ended September 30, 2015 October 30, 2015 Yoshihiko Hatanaka President and CEO Astellas Pharma Inc. 0 Cautionary Statement Regarding Forward-Looking Information This material
R&D Pipeline (November 2005)
R&D Pipeline (November 2005) 1Japan (1)Filed Code No YM905 YM177 YM152 FK463 Generic Name (Filing Date ) solifenacin (Aug 2004) celecoxib (Dec 2002) finasteride (Dec1994) micafungin (July 2004) (Oct 2005)
Financial Results for 1Q/FY2015
Financial Results for 1Q/FY2015 Ending March 31, 2016 July 31, 2015 Yasumasa Masuda Senior Corporate Executive, Chief Financial Officer Astellas Pharma Inc. 0 Cautionary Statement Regarding Forward-Looking
Pfizer Pipeline. November 8, 2012
Pfizer Pipeline November 8, 2012 Disclaimer As some programs are still confidential, some candidates may not be identified in this list. In these materials, Pfizer discloses Mechanism of Action (MOA) information
Changes from Third Quarter Flash Report for the Fiscal Year ending March 2015 announced on February 3, 2015 *1: Marketing authorization of Onoact 150
Annual Flash Report (unaudited) Fiscal Year ended March 31, 2015 Supplemental Information Status of Development Pipeline as of May 12, 2015 I. Main Pipelines Other than ONO-4538 ⅰ. Developments Status
3Q/FY2015 Financial Results
3Q/FY2015 Financial Results Ended December 31, 2015 January 29, 2016 Yasumasa Masuda Senior Corporate Executive, Chief Financial Officer Astellas Pharma Inc. Copyright 2015 Astellas Pharma Inc. 0 Cautionary
Pfizer Independent Grants for Learning & Change Track 2- Annual Meetings: Submission Deadlines, Areas of Interest & Educational Goals
In order to submit a request for general meeting support through Track 2- Annual Meetings the answer to the following questions must be Yes : Does the activity align with Pfizer s areas of interest? (listed
Pfizer Pipeline. August 9, 2012
Pfizer Pipeline August 9, 2012 Disclaimer As some programs are still confidential, some candidates may not be identified in this list. In these materials, Pfizer discloses Mechanism of Action (MOA) information
Annual Flash Report (unaudited) Fiscal Year ended March 31, 2017
Annual Flash Report (unaudited) Fiscal Year ended March 31, 2017 Supplemental nation Status of Development Pipeline as of May 8, 2017. Main Status of Development Pipelines (Oncology) 1. Development Status
Financial Results for FY2013 Ended March 31, May 12, 2014 Yoshihiko Hatanaka President and CEO Astellas Pharma Inc.
0 Financial Results for Ended March 31, 2014 May 12, 2014 Yoshihiko Hatanaka President and CEO Astellas Pharma Inc. 1 Cautionary Statement Regarding Forward-Looking Information This material includes forward-looking
Pfizer Global Medical Grants Annual Meetings: Submission Deadlines, Primary Areas of Interest, & Educational Goals
In order to submit a request for general meeting support for an Annual Meeting, the answers to the following questions must be Yes : Does the activity align with Pfizer s Primary Areas of Interest? (listed
Summary of Strategic Competitive Analysis and Publication Planning
Summary of Strategic Competitive Analysis and Publication Planning Carole Alison Chrvala, PhD 919.545.2149 (Work) 919.951.5230 (Mobile) cchrvala@centurylink.net www.healthmattersmedwriting.com 1 Briefing
Summary of late stage clinical trials. As of Jun. 30, 2018
Summary of late stage clinical trials As of Jun. 30, 2018 The document contains information available on the date indicated in its cover page. The public information of clinicaltrials.gov is continuously
ONO PHARMACEUTICAL CO., LTD.
ONO PHARMACEUTICAL CO., LTD. February 6, 2006 Ono Pharmaceutical Co., Ltd. has announced its consolidated financial results for nine months ended December 31,. This First-Third Quarter Flash Report 2006
Advanced Prostate Cancer. November Jose W. Avitia, M.D
Advanced Prostate Cancer November 4 2017 Jose W. Avitia, M.D In 2017 161,000 new cases of prostate cancer diagnosed in US, mostly with elevated PSA 5-10% will present with metastatic disease In 2017: 26,000
ONO PHARMACEUTICAL CO., LTD.
ONO PHARMACEUTICAL CO., LTD. February 4, 2005 Ono Pharmaceutical Co., Ltd. has announced its consolidated financial results for nine months ended December 31,. This First-Third Quarter Flash Report 2005
Anticholinergic medication use for female overactive bladder in the ambulatory setting in the United States.
Página 1 de 6 PubMed darifenacin vs solifenacin Display Settings:, Sorted by Recently Added Results: 5 1. Int Urogynecol J. 2013 Oct 25. [Epub ahead of print] Anticholinergic medication use for female
Pfizer Pipeline. May 10, 2012
Pfizer Pipeline May 10, 2012 Disclaimer As some programs are still confidential, some candidates may not be identified in this list. In these materials, Pfizer discloses Mechanism of Action (MOA) information
Summary of late stage clinical trials. As of Jul. 22, 2016
Summary of late stage clinical trials As of Jul. 22, 2016 List of abbreviations AE BID DLT GFR iv MTD ORR OS PD PFS PK po PPK Q2W Q3W Q4W QD QW sc TID Adverse Events Twice daily Dose Limiting Toxicity
Major R&D Pipeline As of January 2016
Major R&D Pipeline As of January 2016 Therapeutic area Cardiovascular- Metabolics Phase 1 Phase 2 Phase 3 Application DS-1040 (Acute ischemic stroke / TAFIa DS-2330 (Hyperphosphatemia) DS-9231/TS23 (Thrombosis
Summary of late-stage clinical trials. As of Dec. 31, 2017
Summary of late-stage clinical trials As of Dec. 31, 2017 The document contains information available on the date indicated in its cover page. The public information of clinicaltrials.gov is continuously
Lancet 2008; 372 : CDF. N Engl J Med Aug 28;349(9): J Clin Oncol May 15;19(10): Cancer Nov 1;113(9):2471-7
Tumour Group: UROLOGY Renal Palliative Sunitinib 1 st line therapy Lancet. 1999 Jan 2;353(9146):14-7. Pazopanib 1 st line therapy J Clin Oncol. 2010 28(06):1061-1068 Everolimus 2 nd or 3 rd line in adv./metas.rcc
HEALTH MATTERS, INC. SUMMARY OF PROJECTS AND KEY ACCOMPLISHMENTS TO 2016
Selected 2016 Highlights Epidemiologic research on chronic kidney disease and fistula patency, solid and hematologic malignancies Health economics and outcomes research on beta3-agonist treatment for overactive
Management of Incurable Prostate Cancer in 2014
Management of Incurable Prostate Cancer in 2014 Julie N. Graff, MD, MCR Portland VA Medical Center Assistant Professor of Medicine Knight Cancer Institute, OHSU 2014: Cancer Estimates Stage at Diagnosis
TREATMENT OF OVERACTIVE BLADDER IN ADULTS FUGA 2016 KGH
TREATMENT OF OVERACTIVE BLADDER IN ADULTS FUGA 2016 KGH CONTENTS Overactive bladder (OAB) Treatment of OAB Beta-3 adrenoceptor agonist (Betmiga ) - Panacea? LASER treatment - a flash in the pan or the
Third Quarter Consolidated Financial Results
Third Quarter Consolidated Financial Results for the Fiscal Year Ending March 31, 2014 1. Overview of consolidated results 2. Highlights of Business Performance 3. Actual and Forecast of Main Subsidiary
Pfizer Pipeline. February 28, 2012
Pfizer Pipeline February 28, 2012 Disclaimer As some programs are still confidential, some candidates may not be identified in this list. In these materials, Pfizer discloses Mechanism of Action (MOA)
INDEX OF HEALTH AND WELLNESS NEWS ITEMS January 2013-December 2014
INDEX OF HEALTH AND WELLNESS NEWS ITEMS January 2013-December 2014 Topic (followed by title, month and page number) (Many issues can be found on the KORA website . Complete file is in
Overview of Product Pipeline
Overview of Product Pipeline November 4, 2004 Yamanouchi Pharmaceutical Co., Ltd. Shinji Usuda,, Ph. D. Corporate Vice President Director of Drug Development Division Cautionary statement regarding forward-looking
CHRONIC TREATMENT GUIDELINES
CHRONIC TREATMENT GUIDELINES REGISTRATION OF CHRONIC CONDITIONS You can only access benefits for chronic medication, as listed below, if your prescribing/treating doctor or pharmacist registers your chronic
Gary Scott Friedlander, M.D. Urological Consultants, P.A. A Division of Chesapeake Urology Associates, LLC
Gary Scott Friedlander, M.D. Urological Consultants, P.A. A Division of Chesapeake Urology Associates, LLC 9420 Key West Ave, Suite 420, Rockville, MD 20850 2730 University Blvd, West, Suite 516, Wheaton,
03 May 2016 Page 1 of 5. How does the NHS board decide which new medicines to make available for patients?
NHS Greater Glasgow and Clyde: New Medicines Decisions In Scotland, a newly licensed medicine is routinely available for use in an NHS board only after it has been: accepted for use in the NHSScotland
2015 PQRS Registry. Source Measure Title Measure Description CITIUS1
1 CQ-IQ covers 65 CMS defined measures that Eligible Providers (EPs) have to report on to assess quality of care provided to the patients. Version Supported: PQRS Registry 2015 65 measures Reporting Period:
What is on the Horizon in Drug Therapy for OAB?
What is on the Horizon in Drug Therapy for OAB? K-E Andersson, MD, PhD Wake Forest Institute for Regenerative Medicine Wake Forest University School of Medicine Winston Salem, North Carolina Disclosures
ACUTE LYMPHOBLASTIC LEUKEMIA
ACUTE LYMPHOBLASTIC LEUKEMIA YOUNG ADULT PATIENT Highlights clonoseq Tracking (MRD) Testing in the peripheral blood revealed early signs of relapse post-transplant Patient achieved remission after CAR-T
U.S. FDA Approves New Indication for the Use of XTANDI (enzalutamide) Capsules for Patients with Metastatic Castration-Resistant Prostate Cancer
Astellas Contact: Medivation Contact: Tyler Marciniak Rick Bierly Director, Communications and Advocacy Chief Financial Officer (847) 736-7145 (415) 543-3470 tyler.marciniak@astellas.com Anne Bowdidge
Development pipeline (as of February 1, 2017)
Chugai Pharmaceutical Co., Ltd. (4519) Supplementary Materials for Consolidated Financial Results for FY2016 (IFRS) 13 Development pipeline (as of February 1, 2017) Oncology Additional indication name
Publication Plan 2017
Publication Plan 2017 A passion for turning high quality, independent research insights into actionable commercial intelligence. Why Spherix Global Insights? Our independent reports are designed, developed,
Lower Urinary Tract Symptoms (LUTS) and Nurse-Led Clinics. Sean Diver Urology Advanced Nurse Practitioner candidate Letterkenny University Hospital
Lower Urinary Tract Symptoms (LUTS) and Nurse-Led Clinics Sean Diver Urology Advanced Nurse Practitioner candidate Letterkenny University Hospital 01/02/2018 Lower Urinary Tract Symptoms LUTS - one of
Pharmacotherapy Handbook
Pharmacotherapy Handbook Eighth Edition Barbara G. Wells, PharmD, HP, FCCP, BCPP Dean and Professor Executive Director, Research Institute of Pharmaceutical Sciences School of Pharmacy, The University
Overactive Bladder Syndrome
Overactive Bladder Syndrome behavioural modifications to pharmacological and surgical treatments Dr Jos Jayarajan Urologist Austin Health, Eastern Health Warringal Private, Northpark Private, Epworth Overactive
79 HCCs CMS-HCC Risk Adjustment Model. ICD-10-CM to CMS-HCC Crosswalk. Over 9,500 ICD-10-CM codes map to one or more.
2017 CMS-HCC Risk Adjustment Model Over 9,500 ICD-10-CM codes map to one or more 79 HCCs ICD-10-CM to CMS-HCC Crosswalk CMS-HCC Model On April 4, 2016, the Centers for Medicare & Medicaid Services (CMS)
MATERIALS AND METHODS
Primary Triple Androgen Blockade (TAB) followed by Finasteride Maintenance (FM) for clinically localized prostate cancer (CL-PC): Long term follow-up and quality of life (QOL) SJ Tucker, JN Roundy, RL
Merck Pipeline. November 1, 2017
Merck Pipeline November 1, 2017 Lead-in Language The chart below reflects the Company s research pipeline as of November 1, 2017. Candidates shown in Phase 3 include specific products and the date such
LUNCH AND LEARN. April 17, 2018 David R. Wilkinson M.D. Gulfshore Urology
LUNCH AND LEARN April 17, 2018 David R. Wilkinson M.D. Gulfshore Urology Medical Therapy for Prostate Cancer Androgen (testosterone) is required for the growth of both normal prostate and prostate cancers
David Henry Jablonski, M.D North Mills Avenue Orlando, FL 32803
David Henry Jablonski, M.D. 1812 North Mills Avenue Orlando, FL 32803 EDUCATION: University of Florida College of Medicine, Gainesville, Florida Division of Urology Residency Training Program July 1994-June
Rare Disease Day Brussels, 1 March
Research activities in Europe: Trends and determinants Rare Disease Day Brussels, 1 March 2010 Research Death valley Development Collaboration clinicians / researchers Pharmaceutical Innovation / Performance
NB Drug Plans Formulary Update
Bulletin # 914 October 14, 2015 NB Drug Plans Formulary Update This update to the New Brunswick Drug Plans Formulary is effective October 14, 2015. Included in this bulletin: Special Authorization Benefit
ENROLLMENT : Line of Business Summary
ENROLLMENT : Line of Business Summary Date Range : JAN 2017 through DEC 2017 COMPREHENSIVE MAJOR MEDICAL Print Date : 1/19/2018 9:43:49AM Page 1 of 1 Month Year Single 2 Person : Emp/Spouse 2 Person :
Results Confirm and Extend 40-Week Findings that Treatment with Crysvita is Superior to Conventional Therapy
Ultragenyx and Kyowa Kirin Announce Positive 64-Week Results for Crysvita (burosumab) from Phase 3 Study in Children with X-linked Hypophosphatemia (XLH) Results Confirm and Extend 40-Week Findings that
Clinical AMG - Studies as Principal Investigator since 2009
Clinical Study Experience Dr. Susan Feyerabend Clinical AMG - Studies as LKP since 2009 2009 Extension study of Degarelix versus Goserelin in hormone-naive prostate cancer patients, phase III 2015 Randomized,
Indication Based Pricing and Reimbursement
Indication Based Pricing and Reimbursement Francis Arickx National Institute for Health and Disability Insurance Belgium Conditional Reimbursement Chapter IV TARDIS ERP electronic patient record virtual
2018 KSMO Immune Oncology Forum. Immune checkpoint inhibitors in hematologic. malignancies: evidences and perspectives 서울아산병원종양내과 홍정용
2018 KSMO Immune Oncology Forum Immune checkpoint inhibitors in hematologic malignancies: evidences and perspectives 서울아산병원종양내과 홍정용 2018-07-18 Contents Introduction Immune checkpoint inhibtors in lymphomas
Open clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD
Open clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD London Health Sciences Centre, London, Ontario, Canada BLADDER CANCER A MULTICENTRE, RANDOMIZED PLACEBO-CONTROLLED, DOUBLE-BLIND
Summary of late stage clinical trials. As of Jun. 30, 2017
Summary of late stage clinical trials As of Jun. 30, 2017 The document contains information available on the date indicated in its cover page. The public information of clinicaltrials.gov is continuously
Drug Formulary Update, April 2013
Drug Formulary Update, April 2013 Updates to the HealthPartners Drug Formularies are listed below. Updates for the Commercial Drug Formularies and the Minnesota Health Care Programs (Medicaid and Minnesota
Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements, including statements related to Seattle Genetics corporate priorities, financial guidance and anticipated upcoming activities,
Mrs. Isabelle GAUDIN 22 years experience in Clinical Research LEAD CRA / SENIOR CLINICAL RESEARCH ASSOCIATE
Sté Aid ARC 36, Comba dels Martirs 11570 PALAJA FRANCE Fax : +33 4 68 47 03 52 Mob : +33 6 14 68 71 71 E-mail : isabelle.gaudin@aidarc.com Mrs. Isabelle GAUDIN 22 years experience in Clinical Research
ICD-9-CM CODING FUNDAMENTALS CODING EXERCISES
Steps to Accurate Coding Underline the main term, then locate code: Stenosis of Carotid Artery Transient Ischemic Attack Gastrointestinal hemorrhage Degenerative Joint Disease Coronary Artery Disease Alcoholic
Icd 10 metastatic castration resistant prostate cancer
Icd 10 metastatic castration resistant prostate cancer The Borg System is 100 % Icd 10 metastatic castration resistant prostate cancer Loss of cancer suppressor genes, early in the prostatic carcinogenesis,
National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) Trial design:
Open clinical uro-oncology trials in Canada Eric Winquist, MD, Mary J. Mackenzie, MD, George Rodrigues, MD London Health Sciences Centre, London, Ontario, Canada BLADDER CANCER A PHASE III STUDY OF IRESSA
Consolidated Financial Forecast for the Year Ending March 31,2014 Year ending March 31,2014 Net sales 148,300 $ 1,412,381 Operating income 27, ,
ONO PHARMACEUTICAL CO., LTD. February 4, 2014 Ono Pharmaceutical Co., Ltd. has announced its consolidated financial results for nine months ended December 31, 2013. This First - Third Quarter Flash Report
(generic name: ipilimumab) Injection 50 mg ( Yervoy ), a human anti-human CTLA-4 monoclonal. August 21, 2018
August 21, 2018 Opdivo Approved for Supplemental Applications for Expanded Indications of Malignant Pleural Mesothelioma and Adjuvant Treatment of Melanoma, Change in Dosage and Administration (D&A) of
Developmental Therapeutics for Genitourinary Malignancies
Developmental Therapeutics for Genitourinary Malignancies Russell Szmulewitz, MD April 2018 Disclosure Information 23 rd Annual Developmental Therapeutics Symposium Name of Speaker I have the following
Managing urinary morbidity after brachytherapy. Kieran O Flynn Department of Urology, Salford Royal Foundation Trust, Manchester
Managing urinary morbidity after brachytherapy Kieran O Flynn Department of Urology, Salford Royal Foundation Trust, Manchester Themes Can we predict urinary morbidity? Prevention of urinary morbidity
We re Reaching Ludicrous Speed: New Immunotherapy Oncology Medications
We re Reaching Ludicrous Speed: New Immunotherapy Oncology Medications Adam Peele, PharmD, BCPS, BCOP Oncology Pharmacy Manager Cone Health Disclosures Merck Pharmaceuticals Speaker s Bureau 1 Objectives
Financial Results for the 2Q/FY 2009 Ending March 31, November 6, 2009 Masafumi Nogimori President and CEO Astellas Pharma Inc.
Financial Results for the 2Q/FY 2009 Ending March 31, 2010 November 6, 2009 Masafumi Nogimori President and CEO Astellas Pharma Inc. Cautionary Statement Regarding Forward-Looking Information This material
Development status of OPDIVO (nivolumab) 1
November 2, 2018 Development status of OPDIVO (nivolumab) 1 Target disease JAPAN US/EU KR/TW Melanoma (1 st ) Approved Approved Approved Melanoma (Adjuvant Therapy) Approved Approved(EU) Non-small cell
Internal Medicine Certification Examination Blueprint
Internal Medicine Certification Examination Blueprint What Does the Examination Cover? The exam is designed to evaluate the extent of the candidate s knowledge and clinical judgment in the areas in which
Contents Please refer to Medical Policy I-40 Pertuzumab (Perjeta) for additional information.
May 2018 In This Issue Coverage Guidelines Revised for Azacitidine (Vidaza)... 3 Coverage Guidelines Revised for Fulvestrant (Faslodex)... 4 Place of Service Revised for Total Hip and Total Knee Arthroplasty...
Barbara G. Wells, PharmD, FASHP, FCCP, BCPP Dean and Professor School of Pharmacy, The University of Mississippi Oxford, Mississippi
Barbara G. Wells, PharmD, FASHP, FCCP, BCPP Dean and Professor School of Pharmacy, The University of Mississippi Oxford, Mississippi Joseph T. DiPiro, PharmD, FCCP Panoz Professor of Pharmacy, College
Pfizer Medical Education
Pfizer Medical Education Group Areas of Interest for Grants in Support of Healthcare Quality Improvement and Continuing Professional Development Updated September 2011 The current Clinical Areas of Interest
Pfizer Pipeline. As of January 30, 2018
Pfizer Pipeline As of January 30, 2018 Disclaimer As some programs are still confidential, some candidates may not be identified in this list. In these materials, Pfizer discloses Mechanism of Action (MOA)
ALMIRALL AND IRONWOOD ANNOUNCE POSITIVE RESULTS FROM A PHASE 3 TRIAL WITH LINACLOTIDE IN PATIENTS WITH IRRITABLE BOWEL SYNDROME WITH CONSTIPATION
FOR IMMEDIATE RELEASE Ironwood Contact: Almirall Contact: Susan Brady Ketchum Pleon Corporate Communications Amanda Sefton 617.621.8304 +44 (0) 207.611.3653 sbrady@ironwoodpharma.com amanda.sefton@ketchumpleon.com
Pfizer Pipeline. As of May 1, 2018
Pfizer Pipeline As of May 1, 2018 Disclaimer As some programs are still confidential, some candidates may not be identified in this list. In these materials, Pfizer discloses Mechanism of Action (MOA)
Challenges and controversies of Invasive fungal Infections
Challenges and controversies of Invasive fungal Infections Mona Al-Dabbagh, MD, MHSc Assistant Professor of Pediatrics, COM-KSAU-HS Consultant Pediatric Infectious Diseases and Transplant Infectious Diseases
Definition Prostate cancer
Prostate cancer 61 Definition Prostate cancer is a malignant neoplasm that arises from the prostate gland and the most common form of cancer in men. localized prostate cancer is curable by surgery or radiation
Cancer Immunotherapy Pilot Program/ Patents 4 Patients. USPTO BCP Customer Partnership Meeting Alexandria, VA August 2, 2017
Cancer Immunotherapy Pilot Program/ Patents 4 Patients USPTO BCP Customer Partnership Meeting Alexandria, VA August 2, 2017 1 Cancer Immunotherapy Pilot Program/ Patents 4 Patients The United States Patent
Development pipeline (as of January 31, 2019)
Chugai Pharmaceutical Co., Ltd. (4519) Supplementary Materials for Consolidated Financial Results for FY2018 (IFRS) 14 Development pipeline (as of January 31, 2019) Oncology GA101 / RG7159 Follicular lymphoma